ALTERITY THERAPEUTICS-ADR (ATHE) Stock Fundamental Analysis

NASDAQ:ATHE • US02155X2053

3.37 USD
-0.04 (-1.17%)
Last: Feb 19, 2026, 02:57 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership News
Fundamental Rating

4

Overall ATHE gets a fundamental rating of 4 out of 10. We evaluated ATHE against 521 industry peers in the Biotechnology industry. While ATHE seems to be doing ok healthwise, there are quite some concerns on its profitability. ATHE is valued quite expensively, but it does show have an excellent growth rating.


Dividend Valuation Growth Profitability Health

1

1. Profitability

1.1 Basic Checks

  • ATHE had negative earnings in the past year.
  • In the past year ATHE has reported a negative cash flow from operations.
  • ATHE had negative earnings in each of the past 5 years.
  • In the past 5 years ATHE always reported negative operating cash flow.
ATHE Yearly Net Income VS EBIT VS OCF VS FCFATHE Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 -5M -10M -15M -20M

1.2 Ratios

  • ATHE's Return On Assets of -26.39% is fine compared to the rest of the industry. ATHE outperforms 69.87% of its industry peers.
  • ATHE has a Return On Equity of -28.65%. This is in the better half of the industry: ATHE outperforms 77.16% of its industry peers.
Industry RankSector Rank
ROA -26.39%
ROE -28.65%
ROIC N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ATHE Yearly ROA, ROE, ROICATHE Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 -50 -100 -150

1.3 Margins

  • ATHE does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ATHE Yearly Profit, Operating, Gross MarginsATHE Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 -200K -400K -600K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

6

2. Health

2.1 Basic Checks

  • ATHE does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • ATHE has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
ATHE Yearly Shares OutstandingATHE Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 1M 2M 3M 4M 5M
ATHE Yearly Total Debt VS Total AssetsATHE Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 10M 20M 30M 40M

2.2 Solvency

  • An Altman-Z score of 7.86 indicates that ATHE is not in any danger for bankruptcy at the moment.
  • With a decent Altman-Z score value of 7.86, ATHE is doing good in the industry, outperforming 79.27% of the companies in the same industry.
  • A Debt/Equity ratio of 0.00 indicates that ATHE is not too dependend on debt financing.
  • The Debt to Equity ratio of ATHE (0.00) is comparable to the rest of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 7.86
ROIC/WACCN/A
WACC9.36%
ATHE Yearly LT Debt VS Equity VS FCFATHE Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 10M -10M 20M -20M 30M

2.3 Liquidity

  • A Current Ratio of 12.98 indicates that ATHE has no problem at all paying its short term obligations.
  • With an excellent Current ratio value of 12.98, ATHE belongs to the best of the industry, outperforming 88.10% of the companies in the same industry.
  • A Quick Ratio of 12.98 indicates that ATHE has no problem at all paying its short term obligations.
  • ATHE's Quick ratio of 12.98 is amongst the best of the industry. ATHE outperforms 88.10% of its industry peers.
Industry RankSector Rank
Current Ratio 12.98
Quick Ratio 12.98
ATHE Yearly Current Assets VS Current LiabilitesATHE Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 10M 20M 30M 40M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

7

3. Growth

3.1 Past

  • The Earnings Per Share has grown by an impressive 59.62% over the past year.
  • The Revenue has grown by 66.28% in the past year. This is a very strong growth!
  • Measured over the past years, ATHE shows a very strong growth in Revenue. The Revenue has been growing by 92.01% on average per year.
EPS 1Y (TTM)59.62%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%73.08%
Revenue 1Y (TTM)66.28%
Revenue growth 3Y463.07%
Revenue growth 5Y92.01%
Sales Q2Q%123.33%

3.2 Future

  • The Earnings Per Share is expected to grow by 14.87% on average over the next years. This is quite good.
  • Based on estimates for the next years, ATHE will show a very strong growth in Revenue. The Revenue will grow by 175.12% on average per year.
EPS Next Y-7416.15%
EPS Next 2Y-766.96%
EPS Next 3Y-322.02%
EPS Next 5Y14.87%
Revenue Next Year1197.34%
Revenue Next 2Y248.88%
Revenue Next 3Y399.69%
Revenue Next 5Y175.12%

3.3 Evolution

  • The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
ATHE Yearly Revenue VS EstimatesATHE Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2030 2031 2032 200M 400M 600M 800M
ATHE Yearly EPS VS EstimatesATHE Yearly EPS VS EstimatesYearly EPS VS Estimates 2026 2027 2028 2029 -10 -20 -30 -40

More info and screens

Find the best growth stocksShow best growing peers

0

4. Valuation

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for ATHE. In the last year negative earnings were reported.
  • Also next year ATHE is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ATHE Price Earnings VS Forward Price EarningsATHE Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ATHE Per share dataATHE EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -10 -20 -30

4.3 Compensation for Growth

  • ATHE's earnings are expected to decrease with -322.02% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-766.96%
EPS Next 3Y-322.02%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. Dividend

5.1 Amount

  • No dividends for ATHE!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

ALTERITY THERAPEUTICS-ADR

NASDAQ:ATHE (2/19/2026, 2:57:58 PM)

3.37

-0.04 (-1.17%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)08-29
Earnings (Next)02-26
Inst Owners18.19%
Inst Owner Change-1.24%
Ins Owners2.97%
Ins Owner ChangeN/A
Market Cap61.08M
Revenue(TTM)446.30K
Net Income(TTM)-12.15M
Analysts80
Price Target3.18 (-5.64%)
Short Float %0.01%
Short Ratio0.11
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 193.52
P/FCF N/A
P/OCF N/A
P/B 2.04
P/tB 2.04
EV/EBITDA N/A
EPS(TTM)-0.63
EYN/A
EPS(NY)-30.23
Fwd EYN/A
FCF(TTM)-0.45
FCFYN/A
OCF(TTM)-0.45
OCFYN/A
SpS0.02
BVpS1.65
TBVpS1.65
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -26.39%
ROE -28.65%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0.01
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales 0%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 12.98
Quick Ratio 12.98
Altman-Z 7.86
F-Score5
WACC9.36%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)15.55%
Cap/Sales(5y)732.27%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)59.62%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%73.08%
EPS Next Y-7416.15%
EPS Next 2Y-766.96%
EPS Next 3Y-322.02%
EPS Next 5Y14.87%
Revenue 1Y (TTM)66.28%
Revenue growth 3Y463.07%
Revenue growth 5Y92.01%
Sales Q2Q%123.33%
Revenue Next Year1197.34%
Revenue Next 2Y248.88%
Revenue Next 3Y399.69%
Revenue Next 5Y175.12%
EBIT growth 1Y26.49%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-112.97%
EBIT Next 3Y-52.64%
EBIT Next 5Y8.04%
FCF growth 1Y9.2%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y9.16%
OCF growth 3YN/A
OCF growth 5YN/A

ALTERITY THERAPEUTICS-ADR / ATHE FAQ

What is the fundamental rating for ATHE stock?

ChartMill assigns a fundamental rating of 4 / 10 to ATHE.


What is the valuation status of ALTERITY THERAPEUTICS-ADR (ATHE) stock?

ChartMill assigns a valuation rating of 0 / 10 to ALTERITY THERAPEUTICS-ADR (ATHE). This can be considered as Overvalued.


What is the profitability of ATHE stock?

ALTERITY THERAPEUTICS-ADR (ATHE) has a profitability rating of 1 / 10.


What is the expected EPS growth for ALTERITY THERAPEUTICS-ADR (ATHE) stock?

The Earnings per Share (EPS) of ALTERITY THERAPEUTICS-ADR (ATHE) is expected to decline by -7416.15% in the next year.